Literature DB >> 18417173

Abolished thermal and mechanical antinociception but retained visceral chemical antinociception induced by butorphanol in mu-opioid receptor knockout mice.

Soichiro Ide1, Masabumi Minami, Kumatoshi Ishihara, George R Uhl, Masamichi Satoh, Ichiro Sora, Kazutaka Ikeda.   

Abstract

Butorphanol is hypothesized to induce analgesia via opioid pathways, although the precise mechanisms for its effects remain unknown. In this study, we investigated the role of the mu-opioid receptor (MOP) in thermal, mechanical, and visceral chemical antinociception induced by butorphanol using MOP knockout (KO) mice. Butorphanol-induced thermal antinociception, assessed by the hot-plate and tail-flick tests, was significantly reduced in heterozygous and abolished in homozygous MOP-KO mice compared with wildtype mice. The results obtained from our butorphanol-induced mechanical antinociception experiments, assessed by the Randall-Selitto test, were similar to the results obtained from the thermal antinociception experiments in these mice. Interestingly, however, butorphanol retained its ability to induce significant visceral chemical antinociception, assessed by the writhing test, in homozygous MOP-KO mice. The butorphanol-induced visceral chemical antinociception that was retained in homozygous MOP-KO mice was completely blocked by pretreatment with nor-binaltorphimine, a kappa-opioid receptor (KOP) antagonist. In vitro binding and cyclic adenosine monophosphate assays also showed that butorphanol possessed higher affinity for KOPs and MOPs than for delta-opioid receptors. These results molecular pharmacologically confirmed previous studies implicating MOPs, and partially KOPs, in mediating butorphanol-induced analgesia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417173      PMCID: PMC3769935          DOI: 10.1016/j.neuropharm.2008.03.008

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  26 in total

1.  Unique behavioural phenotypes of recombinant-inbred CXBK mice: partial deficiency of sensitivity to mu- and kappa-agonists.

Authors:  K Ikeda; T Ichikawa; T Kobayashi; T Kumanishi; S Oike; R Yano
Journal:  Neurosci Res       Date:  1999-08       Impact factor: 3.304

2.  Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve.

Authors:  I Sora; G Elmer; M Funada; J Pieper; X F Li; F S Hall; G R Uhl
Journal:  Neuropsychopharmacology       Date:  2001-07       Impact factor: 7.853

3.  A method for measurement of analgesic activity on inflamed tissue.

Authors:  L O RANDALL; J J SELITTO
Journal:  Arch Int Pharmacodyn Ther       Date:  1957-09-01

Review 4.  Peripheral kappa-opioid agonists for visceral pain.

Authors:  Pierre J-M Rivière
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

5.  Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.

Authors:  F Simonin; O Valverde; C Smadja; S Slowe; I Kitchen; A Dierich; M Le Meur; B P Roques; R Maldonado; B L Kieffer
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

6.  Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor.

Authors:  H W Matthes; C Smadja; O Valverde; J L Vonesch; A S Foutz; E Boudinot; M Denavit-Saubié; C Severini; L Negri; B P Roques; R Maldonado; B L Kieffer
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

7.  Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey.

Authors:  L A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  1990-07       Impact factor: 4.030

8.  Butorphanol's efficacy at mu and kappa opioid receptors: inferences based on the schedule-controlled behavior of nontolerant and morphine-tolerant rats and on the responding of rats under a drug discrimination procedure.

Authors:  M J Picker; S S Negus; R M Craft
Journal:  Pharmacol Biochem Behav       Date:  1990-07       Impact factor: 3.533

9.  Effects of nor-binaltorphimine on butorphanol dependence.

Authors:  S P Jaw; M Makimura; B Hoskins; I K Ho
Journal:  Eur J Pharmacol       Date:  1993-08-03       Impact factor: 4.432

10.  Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys.

Authors:  E R Butelman; G Winger; G Zernig; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1995-02       Impact factor: 4.030

View more
  8 in total

Review 1.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

2.  Analgesic and Sedative Effects of Different Doses of Dexmedetomidine Combined with Butorphanol in Continuous Analgesia after a Cesarean Section.

Authors:  Hui Liu; Yalin Wang; Fulong Li; Wei Ren; Li Yuan
Journal:  Front Surg       Date:  2022-05-04

3.  (-)-Pentazocine induces visceral chemical antinociception, but not thermal, mechanical, or somatic chemical antinociception, in μ-opioid receptor knockout mice.

Authors:  Soichiro Ide; Masabumi Minami; George R Uhl; Masamichi Satoh; Ichiro Sora; Kazutaka Ikeda
Journal:  Mol Pain       Date:  2011-04-10       Impact factor: 3.395

4.  Involvement of neutrophils and interleukin-18 in nociception in a mouse model of muscle pain.

Authors:  Shinichirou Yoshida; Yoshihiro Hagiwara; Masahiro Tsuchiya; Masamichi Shinoda; Masashi Koide; Hiroyasu Hatakeyama; Chayanit Chaweewannakorn; Toshihisa Yano; Yasuhito Sogi; Nobuyuki Itaya; Takuya Sekiguchi; Yutaka Yabe; Keiichi Sasaki; Makoto Kanzaki; Eiji Itoi
Journal:  Mol Pain       Date:  2018-01-21       Impact factor: 3.395

5.  Involvement of inflammasome activation via elevation of uric acid level in nociception in a mouse model of muscle pain.

Authors:  Shinichirou Yoshida; Yoshihiro Hagiwara; Masahiro Tsuchiya; Masamichi Shinoda; Masashi Koide; Hiroyasu Hatakeyama; Chayanit Chaweewannakorn; Kazuaki Suzuki; Toshihisa Yano; Yasuhito Sogi; Nobuyuki Itaya; Takuya Sekiguchi; Yutaka Yabe; Keiichi Sasaki; Makoto Kanzaki; Eiji Itoi
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

6.  Comparison of ED95 of Butorphanol and Sufentanil for gastrointestinal endoscopy sedation: a randomized controlled trial.

Authors:  Xiaona Zhu; Limei Chen; Shuang Zheng; Linmin Pan
Journal:  BMC Anesthesiol       Date:  2020-05-02       Impact factor: 2.217

7.  Antinociceptive effects of the combined use of butorphanol and buprenorphine in mice.

Authors:  Kazumasu Sasaki; Tatsuya Ishikawa; Kazutaka Ikeda; Shinya Kasai
Journal:  Neuropsychopharmacol Rep       Date:  2021-09-10

8.  Anesthetic effect of different doses of butorphanol in patients undergoing gastroscopy and colonoscopy.

Authors:  Shun Lv; Defeng Sun; Jinglin Li; Lin Yang; Zhongliang Sun; Yan Feng
Journal:  BMC Surg       Date:  2021-05-27       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.